

Facilitation of Drug Evaluation in Children by Population Methods and Modelling

Michel Tod,^{1,2} Vincent Jullien³ and Gérard Pons³

1 Department of Pharmacy-Toxicology, Hôpital Cochin-Saint Vincent-de-Paul, Paris, France

2 EA 3738, Université Lyon 1, Université de Lyon, Lyon, France

3 Department of Clinical Pharmacology, Hôpital Cochin-Saint Vincent-de-Paul, EAD Inserm U663, Université Paris Descartes, Paris, France

Supplementary Material

This supplementary material contains the 280 references referred to in the full version of this article, which can be found at <http://pharmacokinetics.adisonline.com>.

Annexe

1. Kelman AW, Thomson AH, Whiting B, Bryson SM, Steedman DA, Mawer GE, Samba-Donga LA. Estimation of gentamicin clearance and volume of distribution in neonates and young children. *Br J Clin Pharmacol* 1984; 18 (5): 685-92
2. Grasela Jr TH, Donn SM. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. *Dev Pharmacol Ther* 1985; 8 (6): 374-83
3. Grasela Jr TH, Donn SM. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. *Dev Pharmacol Ther* 1985; 8 (6): 374-83
4. Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW, Whiting B. Population pharmacokinetics of gentamicin in neonates. *Dev Pharmacol Ther* 1988; 11 (3): 173-9
5. Aarons L, Vozeh S, Wenk M, Weiss P, Follath F. Population pharmacokinetics of tobramycin. *Br J Clin Pharmacol* 1989; 28 (3): 305-14
6. Driscoll MS, Ludden TM, Casto DT, Littlefield LC. Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models. *J Pharmacokinet Biopharm* 1989; 17 (2): 141-68
7. Moore ES, Faix RG, Banagale RC, Grasela TH. The population pharmacokinetics of theophylline in neonates and young infants. *J Pharmacokinet Biopharm* 1989; 17 (1): 47-66
8. Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan. *J Clin Pharm Ther* 1989; 14 (1): 71-7
9. Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. *Chem Pharm Bull (Tokyo)* 1990; 38 (7): 1973-6
10. Dodge WF, Jelliffe RW, Richardson CJ, McCleery RA, Hokanson JA, Snodgrass WR. Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. *Clin Pharmacol Ther* 1991; 50 (1): 25-31
11. Fattinger K, Vozeh S, Olafsson A, Vlcek J, Wenk M, Follath F. Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations. *Clin Pharmacol Ther* 1991; 50 (1): 55-65
12. Karlsson MO, Thomson AH, McGovern EM, Chow P, Evans TJ, Kelman AW. Population pharmacokinetics of rectal theophylline in neonates. *Ther Drug Monit* 1991; 13 (3): 195-200
13. Wiest DB, Pinson JB, Gal PS, Brundage RC, Schall S, Ransom JL, Weaver RL, Purohit D, Brown Y. Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus. *Clin Pharmacol Ther* 1991; 49 (5): 550-7
14. Collart L, Blaschke TF, Boucher F, Prober CG. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. *Dev Pharmacol Ther* 1992; 18 (1-2): 71-80
15. Izquierdo M, Lanao JM, Cervero L, Jimenez NV, Dominguez-Gil A. Population pharmacokinetics of gentamicin in premature infants. *Ther Drug Monit* 1992; 14 (3): 177-83
16. Jensen PD, Edgren BE, Brundage RC. Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model. *Pharmacotherapy* 1992; 12 (3): 178-82
17. Tamayo M, Fernandez de Gatta MM, Garcia MJ, Dominguez-Gil A. Population pharmacokinetics of imipramine in children. *Eur J Clin Pharmacol* 1992; 43 (1): 89-92
18. Yukawa E, Higuchi S, Aoyama T. Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. *J Pharm Pharmacol* 1992; 44 (9): 755-60
19. Botha JH, Tyrannes I, Miller R, Wesley A. Determination of theophylline clearance in South African children. *Eur J Clin Pharmacol* 1993; 44 (4): 369-75
20. Ismail R, Rahman AF. Estimation of population pharmacokinetics for carbamazepine in Malaysian patients using the OPT computer program. *J Clin Pharm Ther* 1993; 18 (1): 55-8

21. Karna P, Lee C, Kumar A, Dyke J, Gooch WM, 3rd. Population pharmacokinetics of ceftizoxime in premature newborns. *Dev Pharmacol Ther* 1993; 20 (3-4): 135-43
22. Burtin P, Jacqz-Aigrain E, Girard P, Lenclen R, Magny JF, Betremieux P, Tehiry C, Desplanques L, Mussat P. Population pharmacokinetics of midazolam in neonates. *Clin Pharmacol Ther* 1994; 56 (6 Pt 1): 615-25
23. Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. *Biol Pharm Bull* 1994; 17 (2): 323-6
24. Kataria BK, Ved SA, Nicodemus HF, Hoy GR, Lea D, Dubois MY, Mandema JW, Shafer SL. The pharmacokinetics of propofol in children using three different data analysis approaches. *Anesthesiology* 1994; 80 (1): 104-22
25. Maxwell-Rubin M, Paap CM, Godley PJ. Adequacy of recommended aminophylline loading doses in children. *Am J Hosp Pharm* 1994; 51 (13): 1667-71
26. Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. Population pharmacokinetics of vancomycin in neonates. *Clin Pharmacol Ther* 1994; 56 (2): 169-75
27. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. *Antimicrob Agents Chemother* 1995; 39 (9): 2042-7
28. Botha JH, Gray AL, Miller R. Determination of phenobarbitone population clearance values for South African children. *Eur J Clin Pharmacol* 1995; 48 (5): 381-3
29. Botha JH, Gray AL, Miller R. A model for estimating individualized valproate clearance values in children. *J Clin Pharmacol* 1995; 35 (10): 1020-4
30. Parker EM, Hutchison M, Blumer JL. The pharmacokinetics of meropenem in infants and children: a population analysis. *J Antimicrob Chemother* 1995; 36 Suppl A: 63-71
31. Tanigawara Y, Komada F, Shimizu T, Iwakawa S, Iwai T, Maekawa H, Hori R, Okumura K. Population pharmacokinetics of theophylline. III. Premarketing study for a once-daily administered preparation. *Biol Pharm Bull* 1995; 18 (11): 1590-8
32. Yukawa E. A feasibility study of the multiple-peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. *J Pharm Pharmacol* 1995; 47 (12A): 1048-52
33. Banfield CR, Zhu GR, Jen JF, Jensen PK, Schumaker RC, Perhach JL, Affrime MB, Glue P. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. *Ther Drug Monit* 1996; 18 (1): 19-29
34. Bressolle F, Gouby A, Martinez JM, Joubert P, Saissi G, Guillaud R, Gomeni R. Population pharmacokinetics of amikacin in critically ill patients. *Antimicrob Agents Chemother* 1996; 40 (7): 1682-9
35. Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, Pearson AD, Roche H, Robert A, Newell DR, Canal P. Population pharmacokinetics of carboplatin in children. *Clin Pharmacol Ther* 1996; 59 (4): 436-43
36. Ginsberg B, Howell S, Glass PS, Margolis JO, Ross AK, Dear GL, Shafer SL. Pharmacokinetic model-driven infusion of fentanyl in children. *Anesthesiology* 1996; 85 (6): 1268-75
37. Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ. Population pharmacokinetics of proguanil in patients with acute *P. falciparum* malaria after combined therapy with atovaquone. *Br J Clin Pharmacol* 1996; 42 (5): 589-97
38. Lee TC, Charles BG, Steer PA, Flenady VJ, Grant TC. Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. *Br J Clin Pharmacol* 1996; 41 (3): 191-200
39. Odani A, Hashimoto Y, Takayanagi K, Otsuki Y, Koue T, Takano M, Yasuhara M, Hattori H, Furusho K, Inui K. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. *Biol Pharm Bull* 1996; 19 (3): 444-8

40. Pericloud AP, Avramis VI. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. *Cancer Chemother Pharmacol* 1996; 39 (1-2): 42-50
41. Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, Schaad UB. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. *Antimicrob Agents Chemother* 1996; 40 (1): 29-34
42. Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. *Ther Drug Monit* 1996; 18 (3): 245-53
43. Vinks AA, Mouton JW, Touw DJ, Heijerman HG, Danhof M, Bakker W. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. *Antimicrob Agents Chemother* 1996; 40 (5): 1091-7
44. Yukawa E, Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. *J Clin Pharmacol* 1996; 36 (8): 752-9
45. Zhou XJ, Gruber W, Demmler G, Jacobs R, Reuman P, Adler S, Shelton M, Pass R, Britt B, Trang JM, Whitley RJ, Sommadossi JP. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. *Antimicrob Agents Chemother* 1996; 40 (9): 2202-5
46. Birmingham PK, Tobin MJ, Henthorn TK, Fisher DM, Berkelhamer MC, Smith FA, Fanta KB, Cote CJ. Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: an old drug with new recommendations. *Anesthesiology* 1997; 87 (2): 244-52
47. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Tobramycin population pharmacokinetics in neonates. *Clin Pharmacol Ther* 1997; 62 (4): 392-9
48. Delgado Iribarregay MF, Santo Buelga D, Garcia Sanchez MJ, Otero MJ, Falcao AC, Dominguez-Gil A. Carbamazepine population pharmacokinetics in children: mixed-effect models. *Ther Drug Monit* 1997; 19 (2): 132-9
49. Falcao AC, Fernandez de Gatta MM, Delgado Iribarregay MF, Santos Buelga D, Garcia MJ, Dominguez-Gil A, Lanao JM. Population pharmacokinetics of caffeine in premature neonates. *Eur J Clin Pharmacol* 1997; 52 (3): 211-7
50. Harte GJ, Gray PH, Lee TC, Steer PA, Charles BG. Haemodynamic responses and population pharmacokinetics of midazolam following administration to ventilated, preterm neonates. *J Paediatr Child Health* 1997; 33 (4): 335-8
51. Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children. *Ther Drug Monit* 1997; 19 (1): 29-36
52. Lee TC, Charles B, Steer P, Flenady V, Shearman A. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. *Clin Pharmacol Ther* 1997; 61 (6): 628-40
53. McFadyen ML, Miller R, Ludden TM. Ketotifen pharmacokinetics in children with atopic perennial asthma. *Eur J Clin Pharmacol* 1997; 52 (5): 383-6
54. Postovsky S, Ben Arush MW, Kassis E, Elhasid R, Krivoy N. Pharmacokinetic analysis of gentamicin thrice and single daily dosage in pediatric cancer patients. *Pediatr Hematol Oncol* 1997; 14 (6): 547-54
55. Reynolds LM, Lau M, Brown R, Luks A, Sharma M, Fisher DM. Bioavailability of intramuscular rocuronium in infants and children. *Anesthesiology* 1997; 87 (5): 1096-105
56. Touw DJ, Vinks AA, Neef C. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm. *Pharm World Sci* 1997; 19 (3): 142-51
57. Wallemacq PE, Reding R, Sokal EM, de Ville de Goyet J, Clement de Clety S, Van Leeuw V, De Backer M, Otte JB. Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. *Transpl Int* 1997; 10 (6): 466-70
58. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening. *J Pharm Pharmacol* 1997; 49 (8): 751-6

59. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. *J Clin Pharmacol* 1997; 37 (12): 1160-7
60. Aarons L, Rowland M, Khan A, Taborelli G, Ferrea G, Tarantino V, Fioredda F, Rosina-Parenti R, Cavenaghi L, Borgonovi M. Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children. *Eur J Pharm Sci* 1998; 6 (4): 265-70
61. Anderson BJ, Holford NH, Woollard GA, Chan PL. Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. *Br J Clin Pharmacol* 1998; 46 (3): 237-43
62. Botha JH, du Preez MJ, Miller R, Adhikari M. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. *Eur J Clin Pharmacol* 1998; 53 (5): 337-41
63. Charpiat B, Falconi I, Breant V, Jelliffe RW, Sab JM, Ducerf C, Fourcade N, Thomasson A, Baulieux J. A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. *Ther Drug Monit* 1998; 20 (2): 158-64
64. de Alwis DP, Aarons L, Palmer JL. Population pharmacokinetics of ondansetron: a covariate analysis. *Br J Clin Pharmacol* 1998; 46 (2): 117-25
65. Doz F, Urien S, Chatelut E, Michon J, Rubie H, Zucker JM, Canal P, Bastian G. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children. *Cancer Chemother Pharmacol* 1998; 42 (3): 250-4
66. Gray AL, Botha JH, Miller R. A model for the determination of carbamazepine clearance in children on mono- and polytherapy. *Eur J Clin Pharmacol* 1998; 54 (4): 359-62
67. Mirochnick M, Capparelli E, Dankner W, Sperling RS, van Dyke R, Spector SA. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. *Antimicrob Agents Chemother* 1998; 42 (4): 808-12
68. Samara EE, Gustavson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. *Epilepsia* 1998; 39 (8): 868-73
69. Sanchez-Alcaraz A, Quintana MB, Lopez E, Rodriguez I. Valproic acid clearance in children with epilepsy. *J Clin Pharm Ther* 1998; 23 (1): 31-4
70. Sidhu JS, Ashton M, Huong NV, Hai TN, Karlsson MO, Sy ND, Jonsson EN, Cong LD. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. *Br J Clin Pharmacol* 1998; 45 (4): 347-54
71. Silva R, Reis E, Bispo MA, Almeida AM, Costa IM, Falcao F, Palminha JM, Falcao AC. The kinetic profile of vancomycin in neonates. *J Pharm Pharmacol* 1998; 50 (11): 1255-60
72. Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R. Population pharmacokinetics of vancomycin in Japanese pediatric patients. *Ther Drug Monit* 1998; 20 (6): 612-8
73. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling. *Eur J Clin Pharmacol* 1998; 54 (1): 69-74
74. Anderson BJ, Holford NH, Woollard GA, Kanagasundaram S, Mahadevan M. Perioperative pharmacodynamics of acetaminophen analgesia in children. *Anesthesiology* 1999; 90 (2): 411-21
75. Bailey JM, Miller BE, Lu W, Tosone SR, Kanter KR, Tam VK. The pharmacokinetics of milrinone in pediatric patients after cardiac surgery. *Anesthesiology* 1999; 90 (4): 1012-8
76. du Preez MJ, Botha JH, McFadyen ML, Holford NH. The pharmacokinetics of theophylline in premature neonates during the first few days after birth. *Ther Drug Monit* 1999; 21 (6): 598-603
77. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. *Arch Dis Child Fetal Neonatal Ed* 1999; 81 (3): F221-7

78. Hunt A, Joel S, Dick G, Goldman A. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. *J Pediatr* 1999; 135 (1): 47-55
79. Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H. Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. *Eur J Pharm Sci* 1999; 8 (2): 119-25
80. Lee TC, Charles BG, Harte GJ, Gray PH, Steer PA, Flenady VJ. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. *Anesthesiology* 1999; 90 (2): 451-7
81. Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. *Clin Pharmacol Ther* 1999; 66 (1): 16-24
82. Odoul F, Le Guellec C, Lamagnere JP, Breilh D, Saux MC, Paintaud G, Autret-Leca E. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. *Fundam Clin Pharmacol* 1999; 13 (5): 595-604
83. Preechagoon Y, Charles B, Piotrovskij V, Donovan T, Van Peer A. Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. *Br J Clin Pharmacol* 1999; 48 (5): 688-93
84. Serrano BB, Garcia Sanchez MJ, Otero MJ, Buelga DS, Serrano J, Dominguez-Gil A. Valproate population pharmacokinetics in children. *J Clin Pharm Ther* 1999; 24 (1): 73-80
85. Shader RI, Harmatz JS, Oesterheld JR, Parmelee DX, Sallee FR, Greenblatt DJ. Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. *J Clin Pharmacol* 1999; 39 (8): 775-85
86. Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, Looareesuwan S, Aarons L, White NJ. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. *Clin Pharmacol Ther* 1999; 66 (5): 472-84
87. Vervelde ML, Rademaker CM, Krediet TG, Fleer A, van Asten P, van Dijk A. Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen. *Ther Drug Monit* 1999; 21 (5): 514-9
88. Wurthwein G, Krumpelmann S, Tillmann B, Real E, Schulze-Westhoff P, Jurgens H, Boos J. Population pharmacokinetic approach to compare oral and i.v. administration of etoposide. *Anticancer Drugs* 1999; 10 (9): 807-14
89. Anderson BJ, Woppard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. *Br J Clin Pharmacol* 2000; 50 (2): 125-34
90. Chen C. Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children. *Br J Clin Pharmacol* 2000; 50 (2): 135-45
91. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. *Clin Pharmacol Ther* 2000; 67 (4): 360-7
92. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. *Clin Pharmacol Ther* 2000; 67 (4): 360-7
93. Dempsey D, Jacob P, 3rd, Benowitz NL. Nicotine metabolism and elimination kinetics in newborns. *Clin Pharmacol Ther* 2000; 67 (5): 458-65
94. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. *Antimicrob Agents Chemother* 2000; 44 (3): 697-704
95. Ingwersen SH, Pedersen PC, Groes L, Nielsen KK, Aarons L. Population pharmacokinetics of tiagabine in epileptic patients on monotherapy. *Eur J Pharm Sci* 2000; 11 (3): 247-54
96. Lamarre P, Lebel D, Ducharme MP. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population. *Antimicrob Agents Chemother* 2000; 44 (2): 278-82

97. Lugo Goytia G, Lares-Asseff I, Perez Guille MG, Perez AG, Mejia CL. Relationship between clinical and biologic variables and chloramphenicol pharmacokinetic parameters in pediatric patients with sepsis. *Ann Pharmacother* 2000; 34 (3): 393-7
98. Reynolds LM, Infosino A, Brown R, Hsu J, Fisher DM. Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. *Anesthesiology* 2000; 92 (2): 376-86
99. Sam WJ, Aw M, Quak SH, Lim SM, Charles BG, Chan SY, Ho PC. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. *Br J Clin Pharmacol* 2000; 50 (6): 531-41
100. Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. *Anesthesiology* 2000; 92 (3): 727-38
101. Treluyer JM, Merle Y, Semlali A, Pons G. Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method. *Clin Pharmacol Ther* 2000; 67 (6): 600-9
102. Troconiz IF, Armenteros S, Planelles MV, Benitez J, Calvo R, Dominguez R. Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. *Clin Pharmacokinet* 2000; 38 (6): 505-18
103. Wang J, Liang WQ, Wu JJ, Pan CM. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method. *Acta Pharmacol Sin* 2000; 21 (10): 954-60
104. Wrishko RE, Levine M, Khoo D, Abbott P, Hamilton D. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. *Ther Drug Monit* 2000; 22 (5): 522-31
105. Yukawa E. Investigation of phenobarbital-carbamazepine-valproic acid interactions using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview. *Drug Metabol Drug Interact* 2000; 16 (2): 86-98
106. Anderson BJ, Woollard GA, Holford NH. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. *Eur J Clin Pharmacol* 2001; 57 (8): 559-69
107. Aso R, Ohashi K, Katoh T, Ogata H. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients. *Int J Clin Pharmacol Res* 2001; 21 (3-4): 137-46
108. Bleyzac N, Varnier V, Labaune JM, Corvaisier S, Maire P, Jelliffe RW, Putet G, Aulagner G. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. *Eur J Clin Pharmacol* 2001; 57 (6-7): 499-504
109. Bondareva IB, Sokolov AV, Tischenkova IF, Jelliffe RW. Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage. *J Clin Pharm Ther* 2001; 26 (3): 213-23
110. Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, Kildoo C, Connor JD. The influences of renal function and maturation on vancomycin elimination in newborns and infants. *J Clin Pharmacol* 2001; 41 (9): 927-34
111. Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. *Br J Clin Pharmacol* 2001; 51 (6): 567-76
112. Falcao AC, Buelga DS, Mendez ME, Garcia MJ, Pardo M. Population kinetics of tobramycin in neonates. *Ther Drug Monit* 2001; 23 (3): 202-8
113. Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, Blazquez A, Manzanares J, Urruzuno P, Medina E. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. *Clin Pharmacokinet* 2001; 40 (1): 63-71
114. Hansen TG, Ilett KF, Reid C, Lim SI, Hackett LP, Bergesio R. Caudal ropivacaine in infants: population pharmacokinetics and plasma concentrations. *Anesthesiology* 2001; 94 (4): 579-84
115. Kerbusch T, de Kraker J, Mathjt RA, Beijne JH. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach. *Clin Pharmacokinet* 2001; 40 (8): 615-25

116. Kimura T, Kokubun H, Nowatari M, Matsuura N, Sunakawa K, Kubo H. Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage. *J Antimicrob Chemother* 2001; 47 (1): 51-9
117. Knorr B, Nguyen HH, Kearns GL, Villaran C, Boza ML, Reiss TF, Rogers JD, Zhang J, Larson P, Spielberg S. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. *J Clin Pharmacol* 2001; 41 (6): 612-9
118. Krishna S, Nagaraja NV, Planche T, Agbenyega T, Bedo-Addo G, Ansong D, Owusu-Ofori A, Shroads AL, Henderson G, Hutson A, Derendorf H, Stacpoole PW. Population pharmacokinetics of intramuscular quinine in children with severe malaria. *Antimicrob Agents Chemother* 2001; 45 (6): 1803-9
119. Labaune JM, Bleyzac N, Maire P, Jelliffe RW, Boutroy MJ, Aulagner G, Putet G. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. *Biol Neonate* 2001; 80 (2): 142-7
120. Mentre F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. *J Pharmacokinet Pharmacodyn* 2001; 28 (3): 299-319
121. Mirochnick M, Cooper E, Capparelli E, McIntosh K, Lindsey J, Xu J, Jacobus D, Mofenson L, Bonagura VR, Nachman S, Yoge R, Sullivan JL, Spector SA. Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. *Clin Pharmacol Ther* 2001; 70 (1): 24-32
122. Nath CE, McLachlan AJ, Shaw PJ, Gunning R, Earl JW. Population pharmacokinetics of amphotericin B in children with malignant diseases. *Br J Clin Pharmacol* 2001; 52 (6): 671-80
123. Ouellet D, Bockbrader HN, Wesche DL, Shapiro DY, Garofalo E. Population pharmacokinetics of gabapentin in infants and children. *Epilepsy Res* 2001; 47 (3): 229-41
124. Patoux A, Bleyzac N, Boddy AV, Doz F, Rubie H, Bastian G, Maire P, Canal P, Chatelut E. Comparison of nonlinear mixed-effect and non-parametric expectation maximisation maximisation modelling for Bayesian estimation of carboplatin clearance in children. *Eur J Clin Pharmacol* 2001; 57 (4): 297-303
125. Reith DM, Hooper WD, Parke J, Charles B. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. *J Pharmacokinet Pharmacodyn* 2001; 28 (1): 79-92
126. Sandstrom M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, Ringden O, Oberg G, Bekassy A, Hassan M. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. *Bone Marrow Transplant* 2001; 28 (7): 657-64
127. Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. *J Pharmacokinet Pharmacodyn* 2001; 28 (6): 555-75
128. Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. *Transplantation* 2001; 72 (6): 1056-61
129. Suematsu F, Yukawa E, Yukawa M, Minemoto M, Ohdo S, Higuchi S, Goto Y. Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis. *Eur J Clin Pharmacol* 2001; 57 (1): 19-24
130. Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O, Aujard Y. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. *Antimicrob Agents Chemother* 2001; 45 (1): 150-7
131. Touw DJ, Proost JH, Stevens R, Lafeber HN, van Weissenbruch MM. Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus. *Pharm World Sci* 2001; 23 (5): 200-4
132. Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. *Anesthesiology* 2002; 96 (6): 1336-45
133. Aquerreta I, Aldaz A, Giraldez J, Sierrasesumaga L. Pharmacodynamics of high-dose methotrexate in pediatric patients. *Ann Pharmacother* 2002; 36 (9): 1344-50

134. Avramis VI, Sencer S, Pericloud AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS, Stork L. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. *Blood* 2002; 99 (6): 1986-94
135. Beringer P, Aminimanizani A, Synold T, Scott C. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. *Ther Drug Monit* 2002; 24 (2): 315-21
136. Cremers S, Schoemaker R, Bredius R, den Hartigh J, Ball L, Twiss I, Vermeij P, Vossen J. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. *Br J Clin Pharmacol* 2002; 53 (4): 386-9
137. ES ELD, Nagaraja NV, Derendorf H. Population pharmacokinetics of digoxin in Egyptian pediatric patients: impact of one data point utilization. *Am J Ther* 2002; 9 (6): 492-8
138. Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. *Br J Anaesth* 2002; 89 (3): 428-37
139. Knibbe CA, Melenhorst-de Jong G, Mestrom M, Rademaker CM, Reijnaan AF, Zuideveld KP, Kuks PF, van Vught H, Danhof M. Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. *Br J Clin Pharmacol* 2002; 54 (4): 415-22
140. Lee HS, Khoo YM, Chirino-Barcelo Y, Tan KL, Ong D. Caffeine in apnoeic Asian neonates: a sparse data analysis. *Br J Clin Pharmacol* 2002; 54 (1): 31-7
141. Martin-Suarez A, Falcao AC, Outeda M, Hernandez FJ, Gonzalez MC, Quero M, Arranz I, Lanao JM. Population pharmacokinetics of digoxin in pediatric patients. *Ther Drug Monit* 2002; 24 (6): 742-5
142. Odoul F, Le Guellec C, Henrot A, Saliba E, Levron JC, Saux MC, Paintaud G, Autret-Leca E. Population pharmacokinetics of cisapride in neonates. *Eur J Clin Pharmacol* 2002; 58 (8): 507-13
143. Ririe DG, James RL, O'Brien JJ, Lin YA, Bennett J, Barclay D, Hines MH, Butterworth JF. The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects. *Anesth Analg* 2002; 94 (1): 44-9, table of contents
144. Rousseau A, Sabot C, Delepine N, Delepine G, Debord J, Lachatre G, Marquet P. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. *Clin Pharmacokinet* 2002; 41 (13): 1095-104
145. Schoemaker RC, van der Vorst MM, van Heel IR, Cohen AF, Burggraaf J. Development of an optimal furosemide infusion strategy in infants with modeling and simulation. *Clin Pharmacol Ther* 2002; 72 (4): 383-90
146. Stambaugh JJ, Berning SE, Bulpitt AE, Hollender ES, Narita M, Ashkin D, Peloquin CA. Ofloxacin population pharmacokinetics in patients with tuberculosis. *Int J Tuberc Lung Dis* 2002; 6 (6): 503-9
147. Stolk LM, Degraeuwe PL, Nieman FH, de Wolf MC, de Boer A. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. *Ther Drug Monit* 2002; 24 (4): 527-31
148. Treliyer JM, Merle Y, Tonnelier S, Rey E, Pons G. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. *Antimicrob Agents Chemother* 2002; 46 (5): 1381-7
149. Urien S, Doz F, Namouni F, Bastian G. Pharmacokinetic modelling of total and unbound plasma carboplatin--a population study in 75 children. *Int J Clin Pharmacol Ther* 2002; 40 (6): 270-8
150. Wilens TE, Cohen L, Biederman J, Abrams A, Neft D, Faird N, Sinha V. Fluoxetine pharmacokinetics in pediatric patients. *J Clin Psychopharmacol* 2002; 22 (6): 568-75
151. Wurthwein G, Klingebiel T, Krumpelmann S, Metz M, Schwenker K, Kranz K, Lanvers C, Boos J. Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. *Anticancer Drugs* 2002; 13 (1): 101-10

152. Yukawa E, Satou M, Nonaka T, Yukawa M, Ohdo S, Higuchi S, Kuroda T, Goto Y. Pharmacoepidemiologic investigation of clonazepam relative clearance by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients. *J Clin Pharmacol* 2002; 42 (1): 81-8
153. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, Berning SE, Peloquin CA. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. *Pharmacotherapy* 2002; 22 (6): 686-95
154. Agbenyega T, Planche T, Bedu-Addo G, Ansong D, Owusu-Ofori A, Bhattaram VA, Nagaraja NV, Shroads AL, Henderson GN, Hutson AD, Derendorf H, Krishna S, Stacpoole PW. Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. *J Clin Pharmacol* 2003; 43 (4): 386-96
155. Belldina EB, Huang MY, Schneider JA, Brundage RC, Tracy TS. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. *Br J Clin Pharmacol* 2003; 56 (5): 520-5
156. Botha JH, du Preez MJ, Adhikari M. Population pharmacokinetics of gentamicin in South African newborns. *Eur J Clin Pharmacol* 2003; 59 (10): 755-9
157. de Wildt SN, de Hoog M, Vinks AA, van der Giesen E, van den Anker JN. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. *Crit Care Med* 2003; 31 (7): 1952-8
158. DiCenzo R, Forrest A, Slish JC, Cole C, Guillet R. A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. *Pharmacotherapy* 2003; 23 (5): 585-91
159. Hempel G, Reinhardt D, Creutzig U, Boos J. Population pharmacokinetics of liposomal daunorubicin in children. *Br J Clin Pharmacol* 2003; 56 (4): 370-7
160. Jiao Z, Zhong MK, Shi XJ, Hu M, Zhang JH. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. *Ther Drug Monit* 2003; 25 (3): 279-86
161. Mulla H, McCormack P, Lawson G, Firmin RK, Upton DR. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. *Anesthesiology* 2003; 99 (2): 275-82
162. Panetta JC, Kirstein MN, Gajjar A, Nair G, Fouladi M, Heideman RL, Wilkinson M, Stewart CF. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. *Cancer Chemother Pharmacol* 2003; 52 (6): 435-41
163. Payen S, Serreau R, Munck A, Aujard Y, Aigrain Y, Bressolle F, Jacqz-Aigrain E. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. *Antimicrob Agents Chemother* 2003; 47 (10): 3170-8
164. Petersen KB, Jusko WJ, Rasmussen M, Schmiegelow K. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. *Cancer Chemother Pharmacol* 2003; 51 (6): 465-73
165. Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. *J Clin Pharmacol* 2003; 43 (7): 698-710
166. Sallas WM, Milosavljev S, D'Souza J, Hossain M. Pharmacokinetic drug interactions in children taking oxcarbazepine. *Clin Pharmacol Ther* 2003; 74 (2): 138-49
167. Schiltmeyer B, Klingebiel T, Schwab M, Murdter TE, Ritter CA, Jenke A, Ehninger G, Gruhn B, Wurthwein G, Boos J, Hempel G. Population pharmacokinetics of oral busulfan in children. *Cancer Chemother Pharmacol* 2003; 52 (3): 209-16
168. Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, Sheiner LB. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. *Clin Pharmacol Ther* 2003; 74 (6): 569-80
169. Thomson AH, Kokwaro GO, Muchohi SN, English M, Mohammed S, Edwards G. Population pharmacokinetics of intramuscular gentamicin administered to young infants with suspected severe sepsis in Kenya. *Br J Clin Pharmacol* 2003; 56 (1): 25-31

170. Van Obbergh LJ, Roelants FA, Veyckemans F, Verbeeck RK. In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. *Can J Anaesth* 2003; 50 (6): 593-8
171. Yukawa E, Nonaka T, Yukawa M, Higuchi S, Kuroda T, Goto Y. Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. *J Clin Pharm Ther* 2003; 28 (6): 497-504
172. Allegaert K, Anderson BJ, Naulaers G, de Hoon J, Verbesselt R, Debeer A, Devlieger H, Tibboel D. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. *Eur J Clin Pharmacol* 2004; 60 (3): 191-7
173. Aquerreta I, Aldaz A, Giraldez J, Sierrasesumaga L. Methotrexate pharmacokinetics and survival in osteosarcoma. *Pediatr Blood Cancer* 2004; 42 (1): 52-8
174. Bailey JM, Hoffman TM, Wessel DL, Nelson DP, Atz AM, Chang AC, Kulik TJ, Spray TL, Akbary A, Miller RP, Wernovsky G. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. *J Pharmacokinet Pharmacodyn* 2004; 31 (1): 43-59
175. Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. *J Clin Pharmacol* 2004; 44 (11): 1309-22
176. Bondareva IB, Jelliffe RW, Sokolov AV, Tischenkova IF. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. *J Clin Pharm Ther* 2004; 29 (2): 105-20
177. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. *Br J Anaesth* 2004; 92 (2): 208-17
178. Christensen ML, Mottern RK, Jabbour JT, Fuseau E. Pharmacokinetics of sumatriptan nasal spray in children. *J Clin Pharmacol* 2004; 44 (4): 359-67
179. Corvaisier S, Charpiat B, Mounier C, Wallon M, Leboucher G, Al Kurdi M, Chaulet JF, Peyron F. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. *Antimicrob Agents Chemother* 2004; 48 (10): 3794-800
180. ES ELD, Fuseau E, S ELDA, Cosson V. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. *Eur J Clin Pharmacol* 2004; 59 (11): 783-90
181. Gregoire N, Gualano V, Geneteau A, Milleroux L, Brault M, Mignot A, Roze JC. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. *J Clin Pharmacol* 2004; 44 (10): 1114-24
182. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. *Br J Clin Pharmacol* 2004; 57 (3): 253-62
183. Jiang DC, Wang L. Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. *Acta Pharmacol Sin* 2004; 25 (12): 1576-83
184. Karunajeewa HA, Ilett KF, Dufall K, Kemiki A, Bockarie M, Alpers MP, Barrett PH, Vicini P, Davis TM. Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. *Antimicrob Agents Chemother* 2004; 48 (8): 2966-72
185. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. *Antimicrob Agents Chemother* 2004; 48 (4): 1159-67
186. Krishna R, Krishnaswami S, Kittner B, Sankoh AJ, Jensen BK. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. *Biopharm Drug Dispos* 2004; 25 (9): 373-87
187. Lanao JM, Calvo MV, Mesa JA, Martin-Suarez A, Carabajosa MT, Miguelez F, Dominguez-Gil A. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. *J Antimicrob Chemother* 2004; 54 (1): 193-8

188. Lukas JC, Karikas G, Gazouli M, Kalabalikis P, Hatzis T, Macheras P. Pharmacokinetics of teicoplanin in an ICU population of children and infants. *Pharm Res* 2004; 21 (11): 2064-71
189. Marier JF, Dubuc MC, Drouin E, Alvarez F, Ducharme MP, Brazier JL. Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. *Ther Drug Monit* 2004; 26 (1): 3-8
190. Migoya E, Kearns GL, Hartford A, Zhao J, van Adelsberg J, Tozzi CA, Knorr B, Deutsch P. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. *J Clin Pharmacol* 2004; 44 (5): 487-94
191. Mithwani S, Aarons L, Kokwaro GO, Majid O, Muchohi S, Edwards G, Mohamed S, Marsh K, Watkins W. Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. *Br J Clin Pharmacol* 2004; 57 (2): 146-52
192. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. *Bone Marrow Transplant* 2004; 33 (10): 979-87
193. Pitsiu M, Hussein Z, Majid O, Aarons L, de Longueville M, Stockis A. Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. *Br J Clin Pharmacol* 2004; 57 (4): 402-11
194. Rapp HJ, Molnar V, Austin S, Krohn S, Gadeke V, Motsch J, Boos K, Williams DG, Gustafsson U, Huledal G, Larsson LE. Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. *Paediatr Anaesth* 2004; 14 (9): 724-32
195. Smyth JM, Collier PS, Darwish M, Millership JS, Halliday HL, Petersen S, McElnay JC. Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. *Br J Clin Pharmacol* 2004; 58 (3): 249-58
196. Trenque T, Simon N, Villena I, Chemla C, Quereux C, Leroux B, Jaussaud R, Remy G, Dupouy D, Millart H, Pinon JM, Urien S. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. *Br J Clin Pharmacol* 2004; 57 (6): 735-41
197. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. *Antimicrob Agents Chemother* 2004; 48 (6): 2166-72
198. Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, Ashkin D, Auclair B, Berning SE, Jelliffe RW, Jaresko GS, Peloquin CA. Pharmacokinetics of ethambutol in children and adults with tuberculosis. *Int J Tuberc Lung Dis* 2004; 8 (11): 1360-7
199. Zwaveling J, Bubbers S, van Meurs AH, Schoemaker RC, van Heel IR, Vermeij P, Burggraaf J. Pharmacokinetics of rectal tramadol in postoperative paediatric patients. *Br J Anaesth* 2004; 93 (2): 224-7
200. Allegaert K, Anderson BJ, Verbesselt R, Debeer A, de Hoon J, Devlieger H, Van Den Anker JN, Tibboel D. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. *Br J Anaesth* 2005; 95 (2): 231-9
201. Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. *Paediatr Anaesth* 2005; 15 (4): 282-92
202. Blumer JL, Reed MD, Kaplan EL, Drusano GL. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling. *Pediatrics* 2005; 116 (4): 927-32
203. Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate. *Antimicrob Agents Chemother* 2005; 49 (7): 2760-6
204. Carlsson KC, Hoem NO, Glauser T, Vinks AA. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. *Clin Ther* 2005; 27 (5): 618-26
205. Chalkiadis GA, Anderson BJ, Tay M, Bjorksten A, Kelly JJ. Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. *Br J Anaesth* 2005; 95 (4): 524-9

206. el-Desoky ES, Madabushi R, Amry Sel D, Bhattaram VA, Derendorf H. Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense? *Am J Ther* 2005; 12 (4): 320-7
207. Fukuda T, Yukawa E, Kondo G, Maeda T, Shin-o T, Kondo Y, Immura T, Irikura M, Irie T. Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea. *J Clin Pharm Ther* 2005; 30 (6): 591-6
208. Hussein Z, Pitsiu M, Majid O, Aarons L, de Longueville M, Stockis A. Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. *Br J Clin Pharmacol* 2005; 59 (1): 28-37
209. Jullien V, Urien S, Chappuy H, Dimet J, Rey E, Pons G, Blanche S, Treluyer JM. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis. *J Clin Pharmacol* 2005; 45 (3): 257-64
210. Kirstein MN, Panetta JC, Gajjar A, Nair G, Iacono LC, Freeman BB, 3rd, Stewart CF. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. *Cancer Chemother Pharmacol* 2005; 55 (5): 433-8
211. Knibbe CA, Zuiderveld KP, Aarts LP, Kuks PF, Danhof M. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. *Br J Clin Pharmacol* 2005; 59 (6): 705-11
212. Kuhle S, Massicotte P, Dinyari M, Vegh P, Mitchell D, Marzinotto V, Chan A, Pieniaszek H, Mitchell LG. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. *Thromb Haemost* 2005; 94 (6): 1164-71
213. Laer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Zhang W, Hulpke-Wette M. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. *J Am Coll Cardiol* 2005; 46 (7): 1322-30
214. Le Jouan M, Jullien V, Tetanye E, Tran A, Rey E, Treluyer JM, Tod M, Pons G. Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum. *Antimicrob Agents Chemother* 2005; 49 (9): 3658-62
215. Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. *Br J Clin Pharmacol* 2005; 59 (1): 54-61
216. Payen S, Faye A, Compagnucci A, Giaquinto C, Gibbs D, Gomeni R, Bressolle F, Jacqz-Aigrain E. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. *Antimicrob Agents Chemother* 2005; 49 (2): 525-35
217. Payen S, Zhang D, Maisin A, Popon M, Bensman A, Bouissou F, Loirat C, Gomeni R, Bressolle F, Jacqz-Aigrain E. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. *Ther Drug Monit* 2005; 27 (3): 378-88
218. Ramakrishnan R, Migoya E, Knorr B. A population pharmacokinetic model for montelukast disposition in adults and children. *Pharm Res* 2005; 22 (4): 532-40
219. Sarashina A, Tatami S, Yamamura N, Tsuda Y, Igarashi T. Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. *Br J Clin Pharmacol* 2005; 59 (1): 43-53
220. Shi J, Kovacs SJ, Wang Y, Ludden TM, Bhargava VO. Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. *J Pharmacokinet Pharmacodyn* 2005; 32 (3-4): 419-39
221. Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson AD, Howe K, Chisholm JC, Beane C, Brennan B, Waters F, Glaser A, Hemsworth S, McDowell H, Wright Y, Pritchard-Jones K, Pinkerton R, Jenner G, Nicholson J, Elsworth AM, Boddy AV. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. *Clin Cancer Res* 2005; 11 (16): 5893-9
222. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. *J Clin Pharmacol* 2005; 45 (3): 246-56

223. Yukawa E, Suematsu F, Yukawa M, Minemoto M. Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants. *J Clin Pharm Ther* 2005; 30 (2): 159-63
224. Al Za'abi M, Lanner A, Xiaonian X, Donovan T, Charles B. Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. *Ther Drug Monit* 2006; 28 (6): 793-9
225. Allegaert K, Rayyan M, Anderson BJ. Impact of ibuprofen administration on renal drug clearance in the first weeks of life. *Methods Find Exp Clin Pharmacol* 2006; 28 (8): 519-22
226. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Hutagalung R, Hae R, Singhasivanon P, White NJ, Nosten F. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. *Antimicrob Agents Chemother* 2006; 50 (7): 2281-5
227. Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garcia MJ. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. *Clin Pharmacokinet* 2006; 45 (12): 1227-38
228. Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. *Ther Drug Monit* 2006; 28 (1): 67-72
229. Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathot RA, Huitema AD, Beijnen JH. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. *Pediatr Infect Dis J* 2006; 25 (6): 538-43
230. Du X, Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. *J Clin Pharmacol* 2006; 46 (1): 69-75
231. El-Tahtawy A, Kokki H, Reidenberg BE. Population pharmacokinetics of oxycodone in children 6 months to 7 years old. *J Clin Pharmacol* 2006; 46 (4): 433-42
232. Flynn JT, Nahata MC, Mahan Jr JD, Portman RJ. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. *J Clin Pharmacol* 2006; 46 (8): 905-16
233. Freeman BB, 3rd, Iacono LC, Panetta JC, Gajjar A, Stewart CF. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. *Neuro Oncol* 2006; 8 (2): 89-95
234. Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, Ogura Y, Oike F, Takada Y, Egawa H, Uemoto S, Inui K. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. *Clin Pharmacol Ther* 2006; 80 (4): 331-45
235. Garcia B, Barcia E, Perez F, Molina IT. Population pharmacokinetics of gentamicin in premature newborns. *J Antimicrob Chemother* 2006; 58 (2): 372-9
236. Garrido MJ, Habre W, Rombout F, Troconiz IF. Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. *Pharm Res* 2006; 23 (9): 2014-23
237. Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. *Clin Pharmacokinet* 2006; 45 (11): 1099-114
238. Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, Blanche S, Treluyer JM. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. *Antimicrob Agents Chemother* 2006; 50 (3): 910-6
239. Hong Y, Shaw PJ, Nath CE, Yadav SP, Stephen KR, Earl JW, McLachlan AJ. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. *Antimicrob Agents Chemother* 2006; 50 (3): 935-42
240. Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas JP, Vaz P, Rouzioux C, Chaix ML, Macassa E, Firtion G, Pons G, Blanche S, Treluyer JM. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. *Antimicrob Agents Chemother* 2006; 50 (11): 3548-55

241. Knorr B, Maganti L, Ramakrishnan R, Tozzi CA, Migoya E, Kearns G. Pharmacokinetics and safety of montelukast in children aged 3 to 6 months. *J Clin Pharmacol* 2006; 46 (6): 620-7
242. Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. *J Paediatr Child Health* 2006; 42 (10): 601-5
243. Muller C, Kremer W, Harlfinger S, Doroshenko O, Jetter A, Hering F, Hunseler C, Roth B, Theisohn M. Pharmacokinetics of piritramide in newborns, infants and young children in intensive care units. *Eur J Pediatr* 2006; 165 (4): 229-39
244. Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S. Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma. *Drug Metab Pharmacokinet* 2006; 21 (2): 133-9
245. Osterberg O, Savic RM, Karlsson MO, Simonsson US, Norgaard JP, Walle JV, Agerso H. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. *J Clin Pharmacol* 2006; 46 (10): 1204-11
246. Peeters MY, Prins SA, Knibbe CA, DeJongh J, Mathot RA, Warris C, van Schaik RH, Tibboel D, Danhof M. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. *Anesthesiology* 2006; 105 (6): 1135-46
247. Peeters MY, Prins SA, Knibbe CA, DeJongh J, van Schaik RH, van Dijk M, van der Heiden IP, Tibboel D, Danhof M. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. *Anesthesiology* 2006; 104 (3): 466-74
248. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D. Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. *Clin Pharmacokinet* 2006; 45 (7): 705-14
249. Petroz GC, Sikich N, James M, van Dyk H, Shafer SL, Schily M, Lerman J. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. *Anesthesiology* 2006; 105 (6): 1098-110
250. Pullen J, de Rozario L, Stolk LM, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates. *Ther Drug Monit* 2006; 28 (3): 351-8
251. Pullen J, Stolk LM, Nieman FH, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. *Ther Drug Monit* 2006; 28 (2): 226-31
252. Sam WJ, Tham LS, Holmes MJ, Aw M, Quak SH, Lee KH, Lim SG, Prabhakaran K, Chan SY, Ho PC. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. *Clin Pharmacokinet* 2006; 45 (1): 59-75
253. Shangguan WN, Lian Q, Aarons L, Matthews I, Wang Z, Chen X, Freemantle N, Smith FG. Pharmacokinetics of a single bolus of propofol in chinese children of different ages. *Anesthesiology* 2006; 104 (1): 27-32
254. Simpson JA, Agbenyega T, Barnes KI, Di Perri G, Folb P, Gomes M, Krishna S, Krudsood S, Looareesuwan S, Mansor S, McIlheron H, Miller R, Molyneux M, Mwenechanya J, Navaratnam V, Nosten F, Olliaro P, Pang L, Ribeiro I, Tembo M, van Vugt M, Ward S, Weerasuriya K, Win K, White NJ. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. *PLoS Med* 2006; 3 (11): e444
255. Simpson JA, Hughes D, Manyando C, Bojang K, Aarons L, Winstanley P, Edwards G, Watkins WA, Ward S. Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. *Br J Clin Pharmacol* 2006; 61 (3): 289-300
256. Tabata K, Katashima M, Kawamura A, Kaibara A, Tanigawara Y. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. *Drug Metab Pharmacokinet* 2006; 21 (4): 324-31
257. Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2006; 37 (4): 345-51

258. van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, Rademaker CM. Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. *Ther Drug Monit* 2006; 28 (3): 339-44
259. Zuppa AF, Nicolson SC, Adamson PC, Wernovsky G, Mondick JT, Burnham N, Hoffman TM, Gaynor JW, Davis LA, Greeley WJ, Spray TL, Barrett JS. Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. *Anesth Analg* 2006; 102 (4): 1062-9
260. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. *Br J Clin Pharmacol* 2007; 63 (1): 75-84
261. Avramis VI, Spence SA. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. *J Pediatr Hematol Oncol* 2007; 29 (4): 239-47
262. Bertholle-Bonnet V, Bleyzac N, Galambrun C, Mialou V, Bertrand Y, Souillet G, Aulagner G. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. *Ther Drug Monit* 2007; 29 (2): 177-84
263. Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D, Sahajwalla C, Mehta M, Gobburu JV. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. *J Clin Pharmacol* 2007; 47 (1): 101-11
264. Fanta S, Jonsson S, Backman JT, Karlsson MO, Hoppu K. Developmental pharmacokinetics of cyclosporin - a population pharmacokinetic study in paediatric renal transplant candidates. *Br J Clin Pharmacol* 2007
265. Gupta SK, Kantesaria B, Banfield C, Wang Z. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. *Br J Clin Pharmacol* 2007; 64 (2): 174-84
266. Hempel G, Oechtering D, Lanvers-Kaminsky C, Klingebiel T, Vormoor J, Gruhn B, Boos J. Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan. *J Clin Oncol* 2007; 25 (13): 1772-8
267. Herd D, Anderson BJ. Ketamine disposition in children presenting for procedural sedation and analgesia in a children's emergency department. *Paediatr Anaesth* 2007; 17 (7): 622-9
268. Herd DW, Anderson BJ, Holford NH. Modeling the norketamine metabolite in children and the implications for analgesia. *Paediatr Anaesth* 2007; 17 (9): 831-840
269. Irtan S, Saint-Marcoux F, Rousseau A, Zhang D, Leroy V, Marquet P, Jacqz-Aigrain E. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. *Ther Drug Monit* 2007; 29 (1): 96-102
270. Jullien V, Rais A, Urien S, Dimet J, Delaugerre C, Bouillon-Pichault M, Rey E, Pons G, Blanche S, Treluyer JM. Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis. *Br J Clin Pharmacol* 2007; 64 (1): 105-9
271. Lynn AM, Bradford H, Kantor ED, Seng KY, Salinger DH, Chen J, Ellenbogen RG, Vicini P, Anderson GD. Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. *Anesth Analg* 2007; 104 (5): 1040-51, tables of contents
272. Maier G, Rubino C, Hsu R, Grasela T, Baumgartner RA. Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. *Pulm Pharmacol Ther* 2007; 20 (5): 534-42
273. Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. *Br J Clin Pharmacol* 2007; 64 (2): 151-64
274. Paradisis M, Jiang X, McLachlan AJ, Evans N, Kluckow M, Osborn D. Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. *Arch Dis Child Fetal Neonatal Ed* 2007; 92 (3): F204-9
275. Plard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, Rieutord A, Jacqz-Aigrain E. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. *Cancer Chemother Pharmacol* 2007; 60 (4): 609-20

276. Rubino CM, Capparelli EV, Bradley JS, Blumer JL, Kearns GL, Reed M, Jacobs RF, Cirincione B, Grasela DM. Population pharmacokinetic model for gatifloxacin in pediatric patients. *Antimicrob Agents Chemother* 2007; 51 (4): 1246-52
277. Seaton C, Ignas J, Muchohi S, Kokwaro G, Maitland K, Thomson AH. Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition. *J Antimicrob Chemother* 2007; 59 (4): 681-9
278. Veal GJ, Cole M, Errington J, Pearson AD, Foot AB, Whyman G, Boddy AV. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group. *Br J Cancer* 2007; 96 (3): 424-31
279. Yukawa E, Akiyama K, Suematsu F, Yukawa M, Minemoto M. Population pharmacokinetic investigation of digoxin in Japanese neonates. *J Clin Pharm Ther* 2007; 32 (4): 381-6
280. Zhang X, Lin T, Bertasso A, Evans C, Dorr A, Kolis SJ, Salgo M, Patel I. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. *J Clin Pharmacol* 2007; 47 (4): 510-7